A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells ...

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of ...

In the exploration of aging and health outcomes, epigenetic clocks have emerged as crucial biomarkers. Predominantly developed from data pertaining to ...

Researchers have discovered that the development of blood vessels in the mouse placenta is controlled epigenetically.

Researchers identified genes that could explain why some assisted reproductive technologies, like IVF, carry a higher risk of ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Epigenetic modifiers, enzymes that catalyze covalent modifications on chromatin, play a pivotal role in establishing stable ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

A new study published in Nature Metabolism identified the direct epigenetic effects of two common byproducts of fiber ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...